Untitled

Download a copy of this content.

Healthtrust presents…”Trauma to the Brain? Osmotics are the Game: An Update on Traumatic Brain Injury and Hyperosmolar Therapy”.

Severe brain injury due to trauma is associated with high mortality. Approximately 50,000 people die from a traumatic brain injury (TBI) each year in the United States. Mortality from TBI is usually due to several factors including, elevated intracranial pressure (ICP), severe intracranial hemorrhage and coagulopathy, impaired oxygenation and ventilation, and seizures. Management of TBI is directed towards each of these factors with ICP being a central focus. Use of hyperosmolar agents, such as mannitol and hypertonic saline, is the main treatment modality in reducing intracranial pressure. The optimal agent of choice is controversial based on current data and unique characteristics of each agent. The intent of this educational session is to educate clinicians on current recommendations on managing TBI and to inform providers of the current clinical data surrounding the use of hyperosmolar agents. Throughout this activity, the presenter will provide clinicians with scenarios for potential use and identify notable information when evaluating a patient with TBI.

Learning Objectives for Pharmacists and Nurses  |  At the end of the session, participants should be able to:

1. Describe the literature evaluating the use of hyperosmolar agents in the treatment of traumatic brain injury and identify areas for future research.
2. Identify patients with traumatic brain injury for which treatment with hyperosmolar agents would be appropriate.
3. List the potential risks and benefits of using hyperosmolar agents in the treatment of traumatic brain injury.

Presenter:

Jeffrey C. Obciana, PharmD  |  PGY 2 Emergency Medicine Pharmacy Resident  |  Ernest Mario School of Pharmacy and Robert Wood Johnson University Hospital

Target Audience: Pharmacists & Nurses

Continuing Education Information: 1.0 contact hour approved for Nurses and Pharmacists. Belmont University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  The ACPE Universal Activity Number for this activity is 0863-9999-20-053-L01-P. The activity is approved for 1 hour (.1 CEUs) of continuing education credit for Nurses and Pharmacists who attend the webinar and complete the online evaluation.

California Board of Registered Nursing Approval. Pfiedler is a provider approved by the California Board of Registered Nursing, Provider Number CEP 14944 for 1.0 contact hour.

Note about CE credit: If you plan to obtain credit, stay until the end of the presentation to receive the verification code you will need to obtain your continuing education credit. A reminder that CE credit is individual. No group credit is available. Each person must register for this session and attend the entire webinar in order to receive an email after the event with instructions on how to apply for continuing education credit. Please do not share the code or forward the email you receive to others who did not actually attend the program. If they are not able to be verified on our webinar provider reports and registration list they will not receive credit. Also, please note: If you are joining only by phone, you will not be eligible for credit. You must also log in and join the visual portion of the webinar to be part of our CE provider-required reporting.

Effective June 1, 2019: Belmont College of Pharmacy will no longer issue paper/electronic statements of credit for CE activities. ACPE (our accrediting body) policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit. The official record of credit may be located in the learner’s e-profile in CPE Monitor at www.nabp.net.  A participant, sponsor, faculty member or other individual wanting to file a grievance with respect to any aspect of a program sponsored or co-sponsored by the Belmont COP may contact the Dean of Belmont University College of Pharmacy in writing at david.gregory@belmont.edu. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level of review.